NOVARTIS

Neuroendocrine Tumors Market to grow at 5.1% CAGR (2020-2034) driven by upcoming therapies, rising incident cases, and increased research. Key players include Novartis, ITM Solucin GMBH, Camurus, Bristol Myers Squibb, Rayzebio, Exelixis, Ipsen, Takeda. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size in 6MM.

The Global Neurology Clinical Trials Market is projected to reach USD 5,549.3 million by 2024 and USD 9,231.2 million by 2033 at a CAGR of 5.8%. The market includes treatments for Alzheimer's, Parkinson's, and Huntington's diseases, driven by increased research funding, stem cell therapies, genetic advancements, and AI in trial management. The US market, valued at USD 2,244.8 million in 2024, is expected to grow to USD 3,618.9 million by 2033 at a CAGR of 5.4%. Key players include Novartis, Covance, Medpace, and Charles River Laboratories. Recent trends highlight gene therapies, AI adoption, and growing collaborations.

The Global Neurology Clinical Trials Market is projected to reach USD 5,549.3 million by 2024 and USD 9,231.2 million by 2033, driven by innovations in treatments for Alzheimer's, Parkinson's, and Huntington's diseases. The US market, valued at USD 2,244.8 million in 2024, is expected to grow to USD 3,618.9 million by 2033. Key drivers include increased funding, stem cell therapies, genetic advancements, and AI technology in trial management.

Lonza expanded its Basel facility to double capacity for biologics drug product quality control, including ADCs and prefilled syringes. The new facility received Swissmedic approval for GMP manufacturing, ensuring safety and regulatory compliance. Key trends include manufacturing demand outpacing supply, driven by complex modalities and patient-friendly treatments. Lonza invests in end-to-end offerings for ADCs and prefilled syringes to meet industry needs, simplifying supply chains and offering agility.

Dow Jones Newswires, November 25, 2024 01:15 ET (06:15 GMT)

Global peptide cancer drug market to exceed US$ 18 billion by 2030, with over 30 approved drugs and 230 in clinical trials. Peptides offer targeted, less toxic cancer treatments, with major players like Novartis and emerging firms driving innovation.

Global peptide cancer drug market expected to exceed $18 billion, with over 30 approved drugs and 230 in clinical trials. Peptides offer targeted, less toxic cancer treatments, combining biologics' specificity with small molecules' cost-effectiveness. Major players include Novartis and Roche, with US leading R&D, supported by FDA's expedited approvals.

Novartis to present over 65 abstracts at ASH and SABCS, including 96-week Scemblix results and Kisqali 4-year analysis. Data highlights commitment to cancer and blood disorder treatments.